Literature DB >> 2264021

Effect of a synthetic thrombin-inhibitor MD805 on the reaction between thrombin and plasma antithrombin-III.

A Hijikata-Okunomiya1, S Okamoto, K Wanaka.   

Abstract

MD805, a synthetic thrombin-inhibitor, effectively retarded the time-dependent inactivation of thrombin which was generated endogeneously or added exogeneously in human plasma. The kinetical study of the time-dependent inactivation indicated that the type of inhibition was competitive and the obtained Ki of MD805 for thrombin was 3 x 10(-8)M. MD805 also inhibited the formation of thrombin-ATIII complex. These results indicated that the active site of thrombin was involved in the reaction between thrombin and ATIII, and that MD805 competed with ATIII for thrombin in exactly the same manner as it competed with fibrinogen or synthetic peptide substrates. As a result, MD805 would serve as a protective agent for ATIII from being consumed, in addition to its potent thrombin-inhibitory activity without the aid of ATIII. By contrast, heparin accelerated the time-dependent inactivation rate of thrombin and the formation of thrombin-ATIII complex, which indicates that heparin accelerates the consumption of ATIII.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2264021     DOI: 10.1016/0049-3848(90)90120-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

Review 1.  A synopsis of the clinical uses of argatroban.

Authors:  M Moledina; M Chakir; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

2.  Clinical experience of Argatroban for anticoagulation in cardiovascular surgery.

Authors:  H Ohteki; K Furukawa; H Ohnishi; Y Narita; M Sakai; K Doi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-01

3.  Suppression of prostanoid formation and regulation of peripheral circulation after surgery using thrombin inhibitor (MD805).

Authors:  M Onizuka; S Ishikawa; O Ishibashi; M Suga; K Mitsui; T Mitsui
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

4.  The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer.

Authors:  Julius Semenas; Andreas Hedblom; Regina R Miftakhova; Martuza Sarwar; Rikard Larsson; Liliya Shcherbina; Martin E Johansson; Pirkko Härkönen; Olov Sterner; Jenny L Persson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-28       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.